secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001798749-23-000059
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Therapeutics reports Q3 2023 net loss of $19.6M; Phase 2b/3 trial on track for Q2 2024 data
--------------------------------------------------------------------------------

- Net loss of $19.6M for Q3 2023, compared to $13.6M in Q3 2022; includes $3.2M stock-based compensation.
- R&D expenses rose to $16.9M from $10.8M YoY, driven by higher clinical trial and headcount costs.
- Cash, equivalents and securities totaled $135.2M at September 30, 2023, sufficient to fund operations into 2026.
- IMPAHCT Phase 2b/3 trial of AV-101 for PAH expects topline Phase 2b data in Q2 2024; over 125 sites active globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000059/0001798749-23-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000059/tmb-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-23-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer